Bioerodible endoprostheses and methods of making the same

• US 8,715,339 B2
• Filed: 11/21/2011
• Issued: 05/06/2014
• Est. Priority Date: 12/28/2006
• Status: Expired due to Fees

• Current Assignee: Boston Scientific Scimed, Inc. (Boston Scientific Corporation)
• Original Assignee: Boston Scientific Scimed, Inc. (Boston Scientific Corporation)
• Inventors: Atanasoska, Liliana, Weber, Jan, Warner, Robert W.
• Primary Examiner(s): Isabella, David
• Assistant Examiner(s): Sharma, Yashita
• Application Number:
  US13/300,789
• Publication Number:
  US 20120065726A1
• Time in Patent Office: 897 Days
• Field of Search: 623/1.34, 623/1.44, 623 111- 146, 607/75, 600/13
• US Class Current: 623/1.38
• CPC Class Codes: A61L 31/022 Metals or alloys
• CPC Class Codes: A61L 31/14 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body

Abstract

A bioerodible endoprosthesis erodes by galvanic erosion that can provide, e.g., improved endothelialization and therapeutic effects.

Claims

1. An endoprosthesis, comprising:

a cathode region and an anode region between which a galvanic cell is formed when the endoprosthesis is implanted in the body, and the anode region is degraded by galvanic corrosion; and

a current controlling layer that erodes to control and limit an area of the anode region exposed to body fluid such that current density generated by the galvanic cell is maintained between ±

10 percent during degradation of between 5 percent to 50 percent by weight of the anode region.

2. The endoprosthesis of claim 1, wherein the endoprosthesis undergoes both galvanic corrosion and bioerosion.

3. The endoprosthesis of claim 1, wherein both the cathode region and the anode region are bioerodible.

4. The endoprosthesis of claim 1, wherein the current density is sufficient for tumor treatment, restenosis inhibition or promotion of cell proliferation.

5. The endoprosthesis of claim 1, wherein the cathode region comprises magnesium or magnesium alloy.

6. The endoprosthesis of claim 5, wherein the magnesium alloy comprises materials selected from the group consisting of:

zinc, aluminum, magnesium, lithium, iron, nickel, copper, and alloys thereof.

7. The endoprosthesis of claim 1, wherein the cathode region comprises materials selected from the group consisting of:

iron, platinum, and gold.

8. The endoprosthesis of claim 1, further comprising a polymer coating.

9. The endoprosthesis of claim 1, further comprising a coating selected from the group consisting of:

magnesium oxide, magnesium hydride, and magnesium fluoride.

10. The endoprosthesis of claim 1, wherein the endoprosthesis erodes from one end toward another end.

11. An erodible endoprosthesis, comprising:

a body including a relatively electronegative material and a relatively electropositive material between which a galvanic cell is formed, the body being formed of an alloy including the electronegative material and the electropositive material, the concentration of electronegative and electropositive material varying in the alloy along a length of the body, wherein concentrations of the electronegative and the electropositive materials are tailored along the length such that, when exposed to body fluid, a current density is generated and maintained between ±

10 percent during degradation of between 5 percent to 50 percent by weight of the endoprosthesis.

12. The endoprosthesis of claim 11, wherein the body includes a current-controlling layer.